Attovia (ATTO) 10% Owner Sanofi Buys 300,000 Shares

What Happened Sanofi (reported as a 10% owner) purchased 300,000 shares of Attovia Therapeutics (ATTO) on August 6, 2026 in the company's IPO at $17.00 per share, totaling $5,100,000. On the same date, Sanofi's Series C preferred stock automatically converted into 782,855 shares of Attovia common stock upon the closing of the IPO (conversion reported with N/A price since it was a non-cash conversion).

This is primarily a purchase in the IPO (a buy, not a sale). Following the IPO and the issuance of additional shares, Sanofi’s beneficial ownership of Attovia’s common stock fell below the 10% threshold.

Key Details

• Transaction date: August 6, 2026. Form 4 filed August 7, 2026 (timely).
• Open-market / IPO purchase: 300,000 shares at $17.00 each = $5,100,000 (footnote F2: purchase in the issuer’s IPO).
• Derivative conversion: Series C preferred auto-converted into 782,855 common shares upon IPO (footnote F1); conversion entries show N/A price because it was a non-cash conversion.
• Ownership after transaction: Sanofi’s beneficial ownership dropped below 10% immediately after the IPO (remark).
• Sanofi holds reported securities through wholly-owned subsidiaries (footnote F3).
• Filing status: Not indicated as late.

Context

• The conversion of preferred shares into common is a structural event tied to the IPO, not an independent buy/sell decision; it increases Sanofi’s common shares held but the IPO issuance caused its percent ownership to fall below 10% due to dilution.
• As a large institutional holder (not an individual executive), this filing reflects corporate-level positioning and IPO participation rather than insider executive trading.